Literature DB >> 18499158

Renal ischemic preconditioning improves recovery of kidney function and decreases alpha-smooth muscle actin expression in a rat model.

Marc Olivier Timsit1, Rudy Gadet, Hassen Ben Abdennebi, Ricardo Codas, Palmina Petruzzo, Lionel Badet.   

Abstract

PURPOSE: We determined the role of ischemic preconditioning on renal function and histology in a rat model.
MATERIALS AND METHODS: A total of 34 Sprague-Dawley rats (Janvier Laboratories, Le Genet-St-Isle, France) were divided into 6 groups, including sham operation, ischemic preconditioning alone (5 minutes of bilateral ischemia followed by 5 minutes of reperfusion for 3 cycles), ischemia alone (60 minutes of bilateral renal pedicle clamping), ischemic preconditioning before bilateral ischemia, ischemic preconditioning before ischemia in left nephrectomized rats and ischemic preconditioning of the left kidney alone before 60 minutes of bilateral warm ischemia to assess the effect of left kidney preconditioning on the contralateral kidney. Serum creatinine and malondialdehyde levels were recorded at days 0, 1, 3, 11 and 15. Kidneys were harvested at day 15 for histological study and alpha-smooth muscle actin typing.
RESULTS: At days 1 and 3 serum creatinine and malondialdehyde levels were significantly lower in the ischemic preconditioning group compared to levels in the ischemia alone group. At days 11 and 15 creatinine and malondialdehyde levels were similar in all groups and comparable to levels at day 0. At day 15 ischemic preconditioning kidneys showed significantly decreased fibrosis and alpha-smooth muscle actin expression than ischemia alone kidneys.
CONCLUSIONS: Ischemic preconditioning improves the ability of rat kidney to tolerate subsequent ischemic injury in the first 3 days after reperfusion. Moreover, fibrosis and alpha-smooth muscle actin expression are decreased in ischemic preconditioning kidneys 15 days after reperfusion, suggesting a potential interest of ischemic preconditioning in surgical situations that expose kidneys to prolonged warm ischemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499158     DOI: 10.1016/j.juro.2008.02.043

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Preconditioning and its clinical potential.

Authors:  P Magill; T Murphy; D J Bouchier-Hayes; K J Mulhall
Journal:  Ir J Med Sci       Date:  2009-03-21       Impact factor: 1.568

Review 2.  The Delay Phenomenon: A Compilation of Knowledge across Specialties.

Authors:  Kristy Hamilton; Erik M Wolfswinkel; William M Weathers; Amy S Xue; Daniel A Hatef; Shayan Izaddoost; Larry H Hollier
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-02-21

3.  Evaluation of Nephroprotective Efficacy of Hypoxic Preconditioning in Patients Undergoing Coronary Artery Bypass Surgery.

Authors:  Zhaneta V Vesnina; Yury B Lishmanov; Ekaterina A Alexandrova; Evgeniy A Nesterov
Journal:  Cardiorenal Med       Date:  2016-06-22       Impact factor: 2.041

Review 4.  Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection.

Authors:  Muntasir Billah; Anisyah Ridiandries; Usaid Allahwala; Harshini Mudaliar; Anthony Dona; Stephen Hunyor; Levon M Khachigian; Ravinay Bhindi
Journal:  Oncotarget       Date:  2019-01-04

5.  Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?

Authors:  Takahiro Nohara; Suguru Kadomoto; Hiroaki Iwamoto; Hiroshi Yaegashi; Masashi Iijima; Shohei Kawaguchi; Takashi Shima; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Chikashi Seto; Atsushi Mizokami
Journal:  J Robot Surg       Date:  2021-07-27

6.  Protection against renal ischaemia/reperfusion injury: A comparative experimental study of the effect of ischaemic preconditioning vs. postconditioning.

Authors:  Ahmed A Shokeir; Abdelaziz M Hussein; Amira Awadalla; Ahmed Samy; Azza Abdelaziz; Sheiri Khater; Nashwa Barakat
Journal:  Arab J Urol       Date:  2012-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.